Skip to main content
. 2013 Oct 3;109(9):2453–2461. doi: 10.1038/bjc.2013.609

Figure 1.

Figure 1

Disease-free survival in the intent-to-treat population at 2.75 years: (A) hazard ratio plot of treatment/biomarker interaction; (B) tumours negative for HER1, HER2, or HER3 (n=2874; 68%); and (C) tumours positive for HER1, HER2, or HER3 (n=1351; 32%). Abbreviations: CI=confidence interval; Exe=exemestane; HER=human epidermal growth factor receptor; HR=hazard ratio; O–E=observed minus expected; Tam=tamoxifen; Var=variance.